You are here: Home / Public / News / EMA PRIME: an opportunity for the translation of Nanomedicine?

EMA PRIME: an opportunity for the translation of Nanomedicine?

The European Medicines Agency (EMA) launched PRIME (PRIority MEdicines), a new scheme to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.

EMA PRIME: an opportunity for the translation of Nanomedicine?

The European Medicines Agency (EMA) launched PRIME (PRIority MEdicines), a new scheme to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.


Through PRIME, EMA offers early and proactive support to medicine developers to optimise the generation of robust data on a medicine’s benefits and risks and enable accelerated assessment of medicines applications. This will help patients to benefit as early as possible from therapies that may significantly improve their quality of life.

Accelerated assessment

PRIME builds on the existing regulatory framework and tools already available such as scientific advice and accelerated assessment. This means that developers of a medicine that benefitted from PRIME can expect to be eligible for accelerated assessment at the time of application for a marketing authorisation.

Fostering early dialogue

By engaging with medicine developers early on, PRIME is aimed at improving clinical trial designs so that the data generated is suitable for evaluating a marketing-authorisation application. Early dialogue and scientific advice also ensure that patients only participate in trials designed to provide the data necessary for an application, making the best use of limited resources.

Key benefits for applicants

Once a candidate medicine has been selected for PRIME, the Agency will:

  • appoint a rapporteur from the Committee for Medicinal Products for Human Use (CHMP) or from the Committee on Advanced Therapies (CAT) in the case of an advanced therapy to provide continuous support and help to build knowledge ahead of a marketing-authorisation application;
  • organise a kick-off meeting with the CHMP/CAT rapporteur and a multidisciplinary group of experts, so that they provide guidance on the overall development plan and regulatory strategy;
  • assign a dedicated contact point;
  • provide scientific advice at key development milestones, involving additional stakeholders such as health-technology-assessment bodies, to facilitate quicker access for patients to the new medicine;
  • confirm potential for accelerated assessment at the time of an application for marketing authorisation.

Eligibility criteria

The scheme focuses on medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options. These medicines are considered priority medicines by EMA. To be accepted for PRIME, a medicine has to show its potential to benefit patients with unmet medical needs based on early clinical data.

Further information on EMA's website: www.ema.europa.eu

Logo disruptive medtalk

Nanomed Award 2017

Upcoming Events
NanoBio&Med2017 Nov 22, 2017 - Nov 24, 2017 — Barcelona (spain)
MicroNanoConference - MNC 2017 Dec 12, 2017 - Dec 13, 2017 — Amsterdam (The Netherlands)
Upcoming events…